Search

Lincomycin

Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium _Streptomyces lincolnensis_ in Lincoln, Nebraska. … in use.

Selenium Sulfide

Selenium Sulfide is an antifungal agent as well as a cytostatic agent, slowing the growth of hyperproliferative cells in seborrhea. … Selenium Sulfide is the active ingredient often used in shampoos for the treatment of dandruff, seborrheic dermatitis and tinea capitis, a fungal infection that is primarily a disease of preadolescent

Follitropin

with significantly higher estradiol (E2) levels. … However, a more recent study showed there is may be a slight clinical difference, with the alpha form tending towards a higher pregnancy rate and the beta form tending towards a lower pregnancy rate, but

Calcium phosphate dihydrate

Leniolisib

[L45758] APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and elevating susceptibility to infections … [L45753] Investigations for using leniolisib in primary Sjögren’s syndrome are ongoing.[A258468]

Coenzyme M

Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.[A18572]

Eplerenone

regulatory feedback of aldosterone on renin secretion. … Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative

Triflusal

Triflusal is a 2-acetoxy-4-trifluoromethylbenzoic acid and it is an aspirin chemically-related molecule but not a derivative. … Uriach and Company and even though it is commercialized in different countries it is not approved by the FDA, EMA or HealthCanada.

Talazoparib

[L47236] Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 [A260346] and by the EMA in June 2019.[L47296] It was approved by Health Canada in September 2020. … [L47301] Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate cancer.[L47236, L47301, L47306]

Belatacept

It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. … FDA approved on June 15, 2011.